Lexaria Bioscience Corp. Cash Flow Statement
LEXX|10 years of annual SEC 10-K data (FY2015-FY2025)
Covers operating cash flow, capital expenditures, free cash flow, share buybacks, and dividends paid across 10 fiscal years. All figures from audited SEC 10-K filings.
Lexaria Bioscience Corp. used $5M in operating cash flow and negative free cash flow of $5M in FY2025.
Based on SEC 10-K filings.
Key Data Points
- Altman Z-Score -2.77 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2017 | FY2016 | FY2015 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | -$5.8M | -$6.7M | -$7.3M | -$4.0M | -$4.1M | -$4.2M | -$6.6M | - | - | -$1.6M |
| Depreciation & Amortization | $42.4K | $145.4K | $102.7K | $111.7K | $112.8K | $60.5K | $2.3K | $619 | $0 | - |
| Operating Cash Flow | -$5.0M | -$5.9M | -$4.9M | -$4.0M | -$2.6M | -$3.0M | -$2.5M | -$660.9K | -$1.5M | -$515.8K |
| Capital Expenditures | $43.0K | $33.7K | $49.2K | - | - | $646.2K | $646.2K | $3.1K | $0 | - |
| Free Cash Flow | -$5.0M | -$5.9M | -$4.9M | - | - | -$3.7M | -$3.2M | -$664.0K | -$1.5M | - |
| FCF Margin | -1077.4% | -2614.8% | -1929.8% | - | - | -1640.4% | -730.3% | -1630.6% | -10209.7% | - |